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Abstract
Oxaliplatin, an anticancer drug commonly used to treat colorectal cancer and other tumors, has a number
of serious side effects, most notably neuropathy and ototoxicity. To gain insights into its ototoxic profile,
oxaliplatin was applied to rat cochlear organ cultures. Consistent with it neurotoxic propensity, oxaliplatin
selectively damaged nerve fibers at a very low dose 1 µM. In contrast, the dose required to damage hair
cells and spiral ganglion neurons was 50 fold higher (50 µM). Oxailiplatin-induced cochlear lesions initial-
ly increased with dose, but unexpectedly decreased at very high doses. This non-linear dose response could
be related to depressed oxaliplatin uptake via active transport mechanisms. Previous studies have demon-
strated that axonal degeneration involves biologically active processes which can be greatly attenuated by
nicotinamide adenine dinucleotide (NAD+). To determine if NAD+ would protect spiral ganglion axons and
the hair cells from oxaliplatin damage, cochlear cultures were treated with oxaliplatin alone at doses of 10
µM or 50 µM respectively as controls or combined with 20 mM NAD+. Treatment with 10 µM oxaliplatin
for 48 hours resulted in minor damage to auditory nerve fibers, but spared cochlear hair cells. However,
when cochlear cultures were treated with 10 µM oxaliplatin plus 20 mM NAD+, most auditory nerve fibers
were intact. 50 µM oxaliplatin destroyed most of spiral ganglion neurons and cochlear hair cells with apop-
totic characteristics of cell fragmentations. However, 50 µM oxaliplatin plus 20 mM NAD+ treatment great-
ly reduced neuronal degenerations and hair cell missing. The results suggested that NAD+ provides signifi-
cant protection against oxaliplatin-induced neurotoxicity and ototoxicity, which may be due to its actions of
antioxidant, antiapoptosis, and energy supply.
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Introduction
Platinum-based antineoplastic drugs are widely used
to treat cancer. The member of platinum-based agents in-
cludes cisplatin, carboplatin, oxaliplatin, satraplatin,
nadaplatin, triplatin, etc[1]. The reason to summarize
above drugs as platinum-based agents is because they
are derived from the element platinum. The anti-tumor
mechanism of platinum-based chemotherapeutic agents
works by binding to DNA and forming cross links be-
tween the strands, and then inhibits DNA synthesis and
eventually destroys the tumor cells [2]. Although platinum
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compounds are highly effective anti-tumor agents, their
clinical usage is limited by a number of serious side ef-
fects, such as nephrotoxicity, neurotoxicity, hepatotoxici-
ty, myelosuppression, neutropenia, gastroenteropathy,
ototoxicity, etc[3-25]. However, besides those common
side-effects, the major side effects of platinum com-
pounds are different from each other. For example, cispl-
atin has severe nephrotoxic, neurotoxic, and ototoxic
side effects[9, 12, 21, 23, 24, 26]. Carboplatin is far less ototoxic
and nephrotoxic than cisplatin[5, 27, 28]. The major side ef-
fect of nedaplatin is myelosuppression[29]. In contrast, ox-
aliplatin is considered to be far less nephrotoxic and oto-
toxic than cisplatin; however, it frequently induces senso-
ry neuropathies which is a condition reminiscent audito-
ry neuropathy[30-33]. As the third-generation of plati-
num-based antineoplastic agent, oxaliplatin is extremely
neurotoxic suggesting that it might preferentially dam-
age spiral ganglion neurons, and might be a potential in-
teresting model for study in axonal degenerations [16, 23].
Nicotinamide adenine dinucleotide, abbreviated
NAD+, is a coenzyme with function of electron transfer
actions. However, it is also helpful in many cellular pro-
cesses. The most notable protective function of NAD+ is
to delay the onset and extension of axonal degenerations
by various neurodegenerative injuries, including traumat-
ic injury, ischemia damage, autoimmune encephalomy-
elitis, p53-induced neuron apoptosis, radiation-induced
immunosuppression, etc. [16, 23, 34-45].
Since axonal destruction was a remarkable feature in
oxaliplatin-induced auditory nerve degenerations[16, 23],
while NAD+ has been proved to protect against axonal
degeneration caused by various neurotoxic agents, we
hypothesized that NAD+ might also protect spiral gangli-
on axons and cochlear hair cells from oxaliplatin injury.
To test this hypothesis, the cochlear organotypic cultures
were treated with oxaliplatin or combined with NAD +
for evaluation of protective effects of NAD+.
Materials and Methods
Animal procedures: Sprague-Dawley rat pups on
postnatal day 3 were purchased from Charles River Lab-
oratories (Wilmington, MA) for this study. All experi-
mental procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) of Universi-
ty at Buffalo, and conform to the guidelines issued by
the National Institutes of Health.
Cochlear organotypic cultures: The preparations of
cochlear organotypic cultures have been described in de-
tail in our earlier publications[17, 46-48]. Briefly, rat pups
were decapitated. The cochleae were carefully removed
and placed in Hank’s Balanced Salt Solution (1X GIB-
CO, 14175, Invitrogen, Carlsbad, CA). The cochlear bas-
ilar membrane containing the organ of Corti and spiral
ganglion neurons was micro-dissected and transfered on-
to a collagen gel matrix. A droplet of 15 μl rat tail colla-
gen (Type 1, BD Biosciences, 4236 Bedford, MA, 10 ×
basal medium eagle, BME, Sigma B9638, 2% sodium
carbonate, 9:1:1 ratio) was freshly made and placed in
the center of a 35 mm diameter culture dish (Falcon
1008, Becton Dickinson) and allowed to gel at room tem-
perature for about 30 minutes. Afterward, 1.3 ml of se-
rum-free medium consisting of 2 g bovine serum albu-
min (BSA, Sigma A-4919), 2 ml Serum-Free Supple-
ment (Sigma I-1884), 4.8 ml of 20% glucose (Sigma
G-2020), 0.4 ml penicillin G (Sigma P-3414), 2 ml of
200 mM glutamine (Sigma G-6392), and 190.8 ml of 1X
BME (Sigma B-1522) were added to the culture dish.
The cochlear explants were placed as a flat preparation
on the surface of the collagen gel, and the surface of co-
chlear explants was exactly even with the culture medi-
um. Cochlear explants were cultured overnight for recov-
ery (Forma Scientific 3029, 37oC in 5% CO2). On day
2, the culture medium was removed and replaced with
fresh medium.
Treatment to cochlear explants: After overnight con-
ditioning, cochlear explants were treated with oxaliplatin
with various doses ranging from 10 µM to 5000 µM for
48 h for detection of ototoxic dose-response of oxaliplat-
in. According to our previous experiments dealing with
NAD+ for otoprotections, the concentration of NAD+ at
20 mM was efficient for protection to axon degenera-
tions in cochlear organotypic culture system[17, 44, 45]. To
test if NAD+ can also protect the auditory neurons and
cochlear hair cells from oxaliplatin-induced damage, 20
mM NAD+ was selected for protection against 10 µM or
50 µM oxaliplatin treament. In addition, control cochlear
explants were cultured with standard serum-free medi-
um, and run concurrently with the experimental samples.
Histology: At the end of experiment, the cochlear ex-
plants were fixed with 10% phosphate buffered formalin
for 1 h. After fixation, specimens were rinsed in 0.01 M
PBS, incubated overnight (4 oC) in solution containing
20 µl of mouse anti-neurofilament 200 kD antibody (Sig-
ma N0142, clone N52), 20 µl Triton X-100 (10%), 6 µl
normal goat serum, 154 µl of 0.01 M PBS. Specimens
were then rinsed with 0.01 M PBS, immersed in a solu-
tion containing 2 µl of secondary anti-mouse IgG
TRITC (Sigma T5393), 12 µl normal goat serum, 40 µl
Triton X-100 (10%) and 345 µl of 0.01 M PBS, rinsed
again with 0.01 M PBS for labeling of spiral ganglion
neurons and auditory nerve fibers. Afterwards, speci-
mens were double stained with Alexa Fluor 488 phalloi-
din (Invitrogen A12379) for 30 minutes to label the ste-
reocilia and cuticular plate of hair cells. Specimens were
rinsed in 0.01M PBS, and mounted on glass slides in
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glycerin, coverslipped and examined using a confocal
microscope (Zeiss LSM-510) with appropriate filters for
TRITC (absorption: 544 nm, emission: 572 nm) , and for
Alexa Fluor 488 (excitation 495 nm, emission 519 nm).
Images were stored on a PC computer and evaluated
with software (Zeiss LSM Image Examiner, Adobe Pho-
toshop).
To quantify the neurotoxic activity of oxaliplatin and
protective efficiency of NAD+ against oxaliplatin neuro-
toxicity, the numbers of morphological intact auditory
nerve fibers projecting to the cochlear hair cells were
counted for the control group, oxaliplatin treated groups,
and oxaliplatin (10 µM and 50 µM) plus NAD+ (20µM)
treated groups in a determinate square region under a flu-
orescent microscope on magnification of 630 tines with
a diameter of 143 µm. Counts were obtained from 6 co-
chlear explants (n=6) from each experimental condition.
Three separate counts at each location produce an aver-
age number to reflect the density of auditory nerve fibers
in this location for this cochlea. The statistical analysis
was using a one-way ANOVA followed by New-
man-Keuls post hoc analyses (GraphPad Prism 5 soft-
ware)[44, 47].
Results
Ototoxic dose-response of oxaliplatin: 48 h after cul-
ture, cochlear hair cells and auditory nerve fibers present
normal in controls which was cultured with standard cul-
ture medium (Fig. 1A). Cochlear hair cells were also in-
tact with the low doses of oxaliplatin treatment (1 µM
and 10 µM) (Fig. 1B, 1C). However, the number of audi-
tory nerve fibers began to decrease in comparision with
controls (Fig. 1b, 1C, and Fig. 3). When the concentra-
tion of oxaliplatin was increased to 50 µM, most hair
cells and auditory nerve fibers were destroyed (Fig. 1D).
100 µM oxaliplatin resulted complete destruction in both
cochlear hair cells and auditory nerve fibers (Fig. 1E).
However, some survival hair cells with weak phalloidin
signals and fragmented auditory nerve fibers were seen
48 h after 500 µM oxaliplatin treatment (Fig. 1F). Inter-
estingly, the number of survival cochlear hair cells
shown a tendency to increase 48 h after 1000 µM or
5000 µM oxaliplatin treatment, even though the labeling
of phalloidin on stereocilia was wearing off, but the pro-
file of cuticular plate in some hair cells were still visible
(Fig. 1G, 1H). This may reflect that high dose of oxalipl-
atin can damage the stereocilia bundles, but remaining
the body of hair cells. Unexpectedly, many auditory
nerve fibers present 48 h after the highest concentration
of oxaliplatin treatment (Fig. 1H).
A similar unusual concentration-damage response was
also seen in the soma of spiral ganglion neurons that neu-
ronal damage increased at moderate doses (50 µM, 100
µM, 500 µM, and 1000 µM) (Fig. 2A-2G), but remained
intact at highest concentration of 5000 µM (Fig. 2H).
Figure 2. Photomicrographs show spiral ganglion neurons 48 h af-
ter oxaliplatin treatment. Oxaliplatin concentration is shown in
each panel. Spiral ganglion neurons present normal in control (A),
1µM oxaliplatin (B) and 10µM oxaliplatin treated cochlear ex-
plants (C). Spiral ganglion neurons were condensed or fragmentat-
ed by oxaliplatin treatmnent with doses of 50 µM, 100 µM, 500
µM, or 1000 µM (D, ED, F, G). In contrast, the body of spiral gan-
glion neurons was quite close to the normal value 48 h after 5000
µM oxaliplatin treatment, although the size of soma seems smaller
than control (H).
The quantifications of auditory nerve fibers were as
shown in Figure 3. Clearly, oxaliplatin can damage audi-
tory nerve fibers as low as 1 µM, and the most toxic ef-
Figure 1. Photomicrographs show cochlear organotypic cultures
48 h after oxaliplatin treatment. Oxaliplatin concentration is
shown in each panel. Cochlear hair cells were intact in control
(A), 1µM oxaliplatin (B) and 10µM oxaliplatin treated cochlear
explants (C). However, the density of auditory nerve fibers began
to decrease 48 h after 1µM or 10 µM oxaliplatin treatment (B, C).
50 µM and 100 µM oxaliplatin treatment destroyed most cochlear
hair cells and auditory nerve fibers (D, E). Some survival hair
cells were seen when the concentration of oxaliplatin increased to
500 µM or higher, but the labeling of stereocilia by phalloidin was
very weak (F, G, H). The auditory nerve fibers appear again 48 h
after 5000 µM oxaliplatin treatment (H)
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fects were in the moderate concentrations of 50 µM and
100 µM. However, the damage to auditory nerve fibers
was significantly reduced when the concentration of ox-
aliplatin reached the highest dose, 5000 µM.
Figure 3. Comparison of the mean number of auditory nerve fi-
bers for each treatment condition reviled that moderate concentra-
tion of oxaliplatin (50 µM, and 100µM) resulted in most heavy
damage to auditory nerve fibers.
*Significantly different from control (P < 0.05).
Protective effects of NAD + against oxaliplatin: 10
µM oxaliplatin treatment for 48 h resulted in a minimum
damage to auditory nerve fibers in comparision with con-
trol cochlea (Fig. 4A, 4B). When the cochlear explants
were treated with 10 µM oxaliplatin plus 20 mM NAD+
for 48 h, the auditory nerve fibers present normal (Fig.
4C). Treatment of 50µM mefloquine for 48 h resulted in
a large loss of cochlear hair cells and auditory nerve fi-
bers (Fig. 4D). Additional NAD + at concentration of
20mM rescued many cochlear hair cells and auditory
nerve fibers (Fig. 4E). The quantitative data shows about
20% decrease of auditory nerve fibers in 10 µM oxalipla-
tin treated cochlear explants, while additional 20 mM
NAD + protected auditory nerve fibers completely (Fig.
4F). 50 µM oxaliplatin destroyed about 80% auditory
nerve fibers, however, the survival auditory nerve fibers
were increased to 80% by additional NAD + treatment
(Fig. 4F).
Figure 4. Cochlear hair cells (green fluorescence) and auditory
nerve fibers with spiral ganglion neurons (red fluorescence) pres-
ent normal 48 h after culture with standard culture medium (A).
10 µM oxaliplatin treatment for 48 h did only minimal damage to
auditory nerve fibers (B). Cochlear hair cells and auditory nerve fi-
bers were intact 48 h after 10 µM oxaliplatin plus 20 mM NAD+
treatment (C). 50 µM oxaliplatin destroyed most cochlear hair
cells and auditory nerve fibers (D). However, additional 20 mM
NAD+ rescued many cochlear hair cells and auditory nerve fibers
(E). Comparison of the mean number of auditory nerve fibers for
each treatment condition reviled that additional 20 mM NAD +
treatment significantly rescued the auditory nerve fibers (F). *Sig-
nificantly different from control (P < 0.05). **Significantly differ-
ent from oxaliplatin treatment alone (P < 0.05).
As shown in figure 4B, 10 µM oxaliplatin caused min-
imum damage to auditory nerve fibers, but it did not
damage the soma of spiral ganglion neurons (Fig. 5A).
This suggested that oxaliplatin-induced damage to audi-
tory peripheral neurons begins with auditory nerve fi-
bers. Therefore, again the morphology of spiral ganglion
neurons treated with 10 µM oxaliplatin plus 20 mM
NAD+ without any noticeable injuries (Fig. 5B). Howev-
er, when the concentration of oxaliplatin increased to 50
µM, most spiral ganglion neurons were characteristic of
apoptosis, cell condensation or fragmentation (Fig. 5C).
In contrast, additional 20 mM NAD+ treatment rescued
most spiral ganglion neurons from apoptosis (Fig. 5D).
Figure 5. Spiral ganglion neurons were intact in both 10 µM oxali-
platin or 10 µM oxaliplatin plus 20 mM NAD+ treated cochlear
explants (A, B). 50 µM oxaliplatin treatment for 48 h caused
death of spiral ganglion neurons with characteristics of apoptosis,
cell shrinkage and fragmentation (C). Additional 20 mM NAD +




As a member of platinum-based chemotherapeutics,
oxaliplatin has similar antineoplastic effects and toxic
mechanisms with other platinum reagents, such as cispla-
tin. However, its neurotoxic effects have attracted wide
attention[29-32, 49-53]. In current study, degeneration to axons
and cochlear hair cells were observed after oxaliplatin
treatment in cochlear culture system. The results have es-
tablished that the auditory nerve axons are more vulnera-
ble to oxaliplatin than the hair cells. Because the dose re-
quired to damage hair cells and soma of spiral ganglion
neurons was 50 folds higher than the dosage required to
destroy auditory axons. This is consistent with previous
reports that oxaliplatin is in preference to target the ner-
vous system[16, 23, 50, 52, 54].
As a general rule in toxicity, the more toxic chemicals
the more severe damage to the tissue. However, we found
that oxaliplatin-induced degeneration of auditory axons
and sensory hair cells was greater following exposure to
moderate doses of oxaliplatin (50 µM, and 100 µM). Un-
expectedly, the highest dose of oxaliplatin (5000 µM) did
not cause severe damage to auditory axons. Similarly, co-
chlear hair cells were completely destroyed with moder-
ate dose treatment (100 µM), whereas the survival hair
cells were increased by higher dose of oxaliplatin treat-
ment (1000 µM). This unique phenomenon is very simi-
lar to our previous findings in other platinum based che-
motherapeutics, such as cisplatin, carboplatin, and neda-
platin[11, 12, 17-21, 23-25]. Evidence suggested that cells can de-
tect their surrounding environment, and adjust the partic-
ular channels for chemical import and / or export accord-
ing to intracellular dynamic balance[12, 16, 17, 20, 21, 23-25, 55-60]. It
has been proved that extracellular platinum agents do not
damage cells. To exert their toxic effects, platinum agents
must enter the cell first. For example, cisplatin can be ac-
tivated once it enters the cytoplasm when the chloride at-
oms on cisplatin are displaced by water molecules. The
aquatic cisplatin becomes potent electrophile and then re-
act with nucleic acid to target DNA. In addition, previ-
ous studies have demonstrated that when cisplatin is
transported into the cell, it can bind with glutathione,
and then becomes a cisplatin-glutathione complex to ex-
ert its toxic effects[61]. Therefore, the entry of platinum
agents is the first important step responsible for its fol-
lowing intracellular toxic effects. The platinum import
is via copper transporter importer, Ctr1, and platinum ex-
port is controlled by copper transporter exporters,
ATP7A and ATP7B[11, 12, 17, 19-21, 23, 24, 59, 60, 62-68]. In normal cir-
cumstances, copper / platinum homeostasis is regulated
stringently by copper transporters. If the extracellular con-
centration of copper or platinum was low, it may be easier
to be introduced into the cell by Ctr1. But if the concentra-
tion of copper or platinum was extremely high in extracel-
lular environment, the cell may modulate its copper trans-
porters by increasing export and decreasing import to ac-
complish the purpose of self-protection[11, 12, 16-21, 23-25, 59, 60].
This magic response to toxic effects of platinum agents
was investigated in vitro experimental models, because
the concentration of platinum agents can be simply ad-
justed to a high level in culture conditions that can
arouse cell’s alert[11, 12, 16-21, 23, 25, 60]. However, we have dem-
onstrated that local application of copper sulfate via
round window membrane can also efficiently stimulate
copper transporters for the reaction of self-protection in
vivo[24, 59]. Therefore, regulating copper transporters may
be a promising approach to keep cells away from plati-
num drug-induced injury.
The most prominent ototoxic mechanism of plati-
num-basedreagentsareinvolvedincellapoptosis[8-10,12,14,17,21,23,
24, 69-75]. According to extensive literatures, cell apoptosis be-
comesapparent innuclearshrinkagewhichisalwaysassoci-
ated with positive TUNEL labeling and/ or caspase activa-
tions[8,9,12,17,21-24,48,76-80]. Consequently, nuclear shrinkage, con-
densationandfragmentationhavebeen identifiedascharac-
teristic of apoptosis. In current study, oxaliplatin-induced
death of spiral ganglion neurons was characterized by apop-
tosis with evident cell fragmentations (Fig. 3 and Fig. 5).
This is in conformity with previous literatures.
Another toxic factor, reactive oxygen species or free
radicals also play an important role in platinum-induced
toxicities[12, 81-89]. Besides the direct damage to cells from
excessive reactive oxygen species or free radicals, most
importantly, the oxidative stress can result in cell apopto-
sis. For example, immoderate reactive oxygen species
can induce protein oxidation, disrupt protein synthesis,
alter cytoskeletal components, attack DNA, disrupt ionic
balance, interfere with cellular signaling, break calcium
homeostasis, damage DNA repair, and interfere with
transcription processes etc, which triggers the apoptotic
signals to start the programmed cell death[90-93].
NAD+ and its relative NAD phosphate (NADP+) play
essential role in many biochemical reactions, especially
redox reactions in which oxidoreductase enzymes trans-
fer hydrogen and electrons from one reaction to another
in the respiratory chain in the cell. However, a growing
evidences support the fact that NAD metabolism regu-
lates many important biological effects including life
span. NAD + , through poly-ADP-ribosyl polymerase
(PARP), mono-ADP-ribosyltransferase (ARTs) and re-
cently characterized sirtuin enzymes, exerts potential bio-
logical effects. NAD + is also involved in adding or re-
moving chemicals from proteins as a substrate of en-
zymes in a manner of posttranslational modifications. In
addition, the antioxidant effect of NAD+ or NAD+ de-
pendent enzymes could be also as a protective function
against cell injury[35, 44, 45]. Many studies have demonstrat-
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ed that a decrease in axonal NAD+ is common in degen-
erating axons triggered by various mechanical and chem-
ical insults[38-40]. Lacking of NAD+ may also be involved
in oxaliplatin-induced axon degenerations in the co-
chlea. NAD-dependent deacetylase activity of Sirt1
could regulate death/survival decision against p53 apop-
totic pathway in mammalian cells[34, 94-96]. As a crucial sub-
strate of Sir2 (silent information regulator 2), NAD+ has
been implicated in influencing for diverse biological
roles including gene silencing, DNA damage repair, cell
cycle regulation, and life span extension by anti-apopto-
sis[34, 94-100]. Deacetylase stress was recognized as a key
molecule for cellular metabolism in organisms. NAD +
serves as cofactor with dehydrogenases for both aerobic
and anaerobic ATP generation. In addition, NAD + acts
as an important substrate for protein of PARP [poly
(ADP-rebose) polymerase], which is a protein involved
in a number of cellular processes. Especially, PARP is in
immediate cellular response to apoptosis, involving
mainly DNA repair and against programmed cell death.
Therefore, one of the most important functions of PARP
is to detect and repair the single strand DNA breaks
against caspase cleavage in apoptosis, which requires
NAD+ as a the essential substrate[101-103]. Considering evi-
dent fact of decrease of NAD+ always associate with ax-
on degeneration in various experimental models[38-40],
when the level of NAD + was decreased in the cell, it
may trigger multiple apoptotic signaling pathways to
start the cell apoptosis. In contrast, increase of NAD +
can prevent axonal NAD + decline efficiently that can
protect axons from degeneration[38-41]. In current study,
the survival rate of auditory nerve fibers was significant-
ly increased when the cochlear explants were treated
with NAD + which efficiently protected auditory axons
from oxaliplatin neurotoxicity. These findings are consis-
tent with previous studies showing that axonal degenera-
tions can be prevented or protected by NAD+ in various
experimental models[38, 39, 41]. Surprisingly, we found that
NAD+ can also prevent cochlear hair cell damage from
oxaliplatin in current study. As particular sensorineural
epithelium, cochlear hair cells are directly connected to
auditory afferent synaptic junctions, which are character-
istic of neurons, such as secreting neurotransmitters that
might be injured by oxaliplatin similarly to its neurotox-
ic effects with decrease of NAD + . The decreased ATP
level was always being found in parallel with NAD+ re-
duction in degenerating cells[39]. Therefore, NAD+ deple-
tion may also impair energy production that triggering
the onset of cell apoptosis. However, the exogenously
providing NAD can effectively delay the decrease of
ATP levels in degenerating cells[39]. Importantly, addi-
tional NAD + treatment can activate Sirt1 and Sirt2
which are positive regulators for anti-apoptosis. There-
fore, the protective effects of NAD + to auditory axons
and cochlear hair cells against oxaliplatin may be also
benefited from mobilizing of intrinsic anti-apoptotic re-
actions. Taking all factors into consideration, the effi-
cient protective effects of NAD+ against oxaliplatin-in-
duced cochlear degeneration may benefit from antioxi-
dant effects, anti-apoptotic effects, and energy supply
from additional NAD+ treatment.
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